Investor News

Acorda Therapeutics Receives Two Grants For Spinal Cord Injury Research

10/20/2003

$380,000 Will Help Advance Program for Extracellular Matrix Modification

Hawthorne, NY October 20, 2003 – Acorda Therapeutics announced today that it has been awarded two grants to support its research program in extracellular matrix modification. The first is a two-year, $280,000 grant from the Spinal Cord Injury Research Board of the New York State Department of Health. The second is a $107,000, six-month Phase 1 grant from the National Institute of Neurological Disorders and Stroke (NINDS).

A key factor in the inability of the central nervous system to repair its connections following injury is the formation of fibrous scar tissue at the site of injury, which serves to inhibit regrowth of injured nerve fibers. Acorda"s research program is built around the concept of breaking down scar tissues that develop as a result of an injury.

About Acorda

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury, multiple sclerosis and related central nervous system disorders. In 2002, Acorda was the recipient of the National Spinal Cord Injury Association"s L. W. Freeman Award for scientific research.

Stock Quote

ACOR (Common Stock) $ 6.80 -0.10 (-1.45%) Volume: 204,125 MORE July 22, 2019

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.